Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 122.30% | -21.46% | -14.87% | 74.23% | -181.91% |
| Total Depreciation and Amortization | 2.33% | 59.26% | 118.92% | 428.57% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -748.28% | 420.21% | -191.17% | -96.40% | 4,198.06% |
| Change in Net Operating Assets | 73.92% | 146.48% | -220.45% | 213.02% | -215.52% |
| Cash from Operations | -37.07% | 38.29% | -141.90% | 52.66% | -21.44% |
| Capital Expenditure | -- | 100.00% | 93.39% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 93.39% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 89.66% | -95.19% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | -100.97% | 163.33% | -96.61% | -- | -- |
| Foreign Exchange rate Adjustments | -111.54% | 503.25% | -370.51% | 55.66% | -28.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,070.15% | 91.95% | -127.99% | 484.68% | -22.67% |